
==== Front
Arch Dermatol Res
Arch Dermatol Res
Archives of Dermatological Research
0340-3696
1432-069X
Springer Berlin Heidelberg Berlin/Heidelberg

39023568
3182
10.1007/s00403-024-03182-y
Original Paper
Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo
http://orcid.org/0000-0003-4338-2662
Yamaguchi Yuji 1
Peeva Elena 2
http://orcid.org/0000-0001-7948-8536
Duca Ester Del 3
http://orcid.org/0000-0002-5171-9854
Facheris Paola 34
http://orcid.org/0000-0001-7366-9416
Bar Jonathan 35
http://orcid.org/0009-0000-7928-1578
Shore Ronald 6
Cox Lori Ann 2
http://orcid.org/0000-0003-0567-1949
Sloan Abigail 7
http://orcid.org/0000-0001-8513-550X
Thaçi Diamant 8
http://orcid.org/0000-0003-4944-9274
Ganesan Anand 9
http://orcid.org/0000-0003-3302-5098
Han George 10
http://orcid.org/0000-0002-5468-4589
Ezzedine Khaled 11
http://orcid.org/0000-0002-0426-0382
Ye Zhan 2
http://orcid.org/0000-0002-9363-324X
Guttman-Yassky Emma emma.guttman@mountsinai.org

3
1 grid.410513.2 0000 0000 8800 7493 Inflammation & Immunology Research Unit, Pfizer, Collegeville, PA USA
2 grid.410513.2 0000 0000 8800 7493 Inflammation & Immunology Research Unit, Pfizer, Cambridge, MA USA
3 grid.59734.3c 0000 0001 0670 2351 Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine, Mount Sinai, New York, NY USA
4 https://ror.org/05d538656 grid.417728.f 0000 0004 1756 8807 IRCCS Humanitas Research Hospital, Milan, Italy
5 https://ror.org/04mhzgx49 grid.12136.37 0000 0004 1937 0546 Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
6 Ronald N. Shore Dermatology, Rockville, MD USA
7 grid.410513.2 0000 0000 8800 7493 Clinical Statistics, Pfizer, Cambridge, MA USA
8 https://ror.org/00t3r8h32 grid.4562.5 0000 0001 0057 2672 Institut fuer Entzuendungsmedizin, University of Luebeck, Luebeck, Germany
9 grid.266093.8 0000 0001 0668 7243 Department of Dermatology, University of California, Irvine, Irvine, CA USA
10 grid.512756.2 0000 0004 0370 4759 Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY USA
11 grid.412116.1 0000 0004 1799 3934 Department of Dermatology, Hôpital Henri Mondor, Créteil, France
18 7 2024
18 7 2024
2024
316 7 47822 5 2024
22 5 2024
15 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The efficacy of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, on active and stable lesions was evaluated in patients with active non-segmental vitiligo in a phase 2b trial (NCT03715829). Patients were randomized to placebo or daily ritlecitinib 50 mg (with or without 4-week 100-mg or 200-mg loading dose), 30 mg, or 10 mg for 24 weeks. Active lesions showed greater baseline expression of inflammatory/immune markers IFNG and CCL5, levels of CD103, and T-cell infiltrates than stable lesions. Patients with more active than stable vitiligo lesions showed higher baseline serum levels of CXCL9 and PD-L1, while patients with more stable than active lesions showed higher baseline serum levels of HO-1. At Week 24, ritlecitinib 50 mg significantly stabilized mean percent change from baseline in depigmentation extent in both active lesions and stable lesions vs. placebo-response, with stable lesions showing greater repigmentation. After 24 weeks of treatment, ritlecitinib 50 mg increased expression of melanocyte markers in stable lesions, while Th1/Th2-related and co-stimulatory molecules decreased significantly in both stable and active lesions. Serum from patients with more active than stable lesions showed decreased levels of ICOS and NK cell activation markers. These data, confirmed at transcription/protein levels, indicate that stable lesion repigmentation occurs early with ritlecitinib, while active lesions require stabilization of inflammation first. ClinicalTrials.gov: NCT03715829.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00403-024-03182-y.

Keywords

Ritlecitinib
Vitiligo
Non-segmental vitiligo
JAK inhibitor
Biomarkers
http://dx.doi.org/10.13039/100004319 Pfizer issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

Vitiligo is an autoimmune disease characterized by depigmentation in the skin, hair, or both, with a global burden affecting an estimated 0.5-2% of the population [1, 2]. In patients with vitiligo, CD8+ T cells attack melanocytes, resulting in non-scaly chalky-white amelanotic lesions [3, 4].

An abnormal adaptive immune response from cytotoxic CD8+ T cells produces cytokines typical of T helper Types 1, 2, and 17 (Th1, Th2, and Th17) immune responses, including interferon (IFN)-γ [5, 6]. The Th1 and Th2 immune responses in turn activate the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway [7], leading to increased levels of IFN-γ that drives decreased melanocyte adhesion [8]. Furthermore, chemokines such as C-X-C motif chemokine ligand (CXCL) 9, CXCL10, and CXCL11 are released, creating a positive feedback loop [5, 9, 10].

Patients with non-segmental vitiligo (NSV) may have stable lesions, which may remain unchanged for at least 6 months, and active lesions that continue to progress simultaneously depending on disease activity [11]. Previous publications have described differences between patients with stable lesions and patients with active lesions at the serological and biochemical levels [12]. Skin biopsy studies have also shown differences, including: (1) greater vacuolar changes of basal keratinocytes and lymphocyte infiltration in the upper dermis, (2) lower adhesion of melanocytes to collagen type IV, and (3) higher expression levels of caspase 3, annexin V, superoxide dismutase, glutathione peroxidase, and malondialdehyde in patients with active lesions vs. patients with stable lesions [12]. In several studies over the past decade, patients with active lesions (compared with patients with stable lesions) show: decreased blood regulatory T cells (Tregs) and CD4+/CD8+ T-cell ratio [13], increased serum CXCL9 and CXCL10 [14], increased serum CCL20 [15], increased CD8+ T cells and expression of E-cadherin in the epidermis and dermis [16], increased CXCL10 in peri-lesional skin [17], and increased CXCL9 and CXCL10 in suction blister fluid [18]. These findings may indicate that active and stable lesions display differential profiles of immune cells and activation of the JAK/STAT pathway.

Current treatments for vitiligo often have limited efficacy and/or undesirable side effects [19–23]. Interest in JAK/STAT pathway inhibition downstream of disease-associated cytokines such as IFN-γ as a potential treatment for vitiligo has grown in recent years and resulted in several clinical trials [24–28] and the approval of ruxolitinib cream, a topical JAK1/2 inhibitor for the treatment of NSV [28, 29].

Ritlecitinib, an oral selective inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases [25], is approved for the treatment of alopecia areata [30], and is currently under investigation for the treatment of NSV. In a phase 2b trial (NCT03715829), ritlecitinib demonstrated significant improvement in the Facial Vitiligo Area Scoring Index and immune and melanocyte biomarkers at Week 24 in patients with active NSV [31, 32]. The main objectives of this report were to evaluate the efficacy of ritlecitinib vs. placebo on active and stable lesions in patients with vitiligo who participated in the phase 2b trial, and to explore the effect of ritlecitinib on melanocyte and immune biomarkers in active and stable lesions.

Methods

Trial design and patients

This was an exploratory analysis of the randomized, double-blind, placebo-controlled, 24-week dose-ranging period of the phase 2b NCT03715829 study [31]. The study protocol and all other documentation were approved by each study center’s institutional review board or independent ethics committee. This study followed the Declaration of Helsinki and the good clinical practice guidelines put forth by the International Conference on Harmonization. All patients provided written informed consent.

Inclusion criteria included adult patients with active NSV who had ≥ 1 active vitiligo lesion. Other criteria included a body surface area (BSA) of 4–50% (excluding acral lesions) and facial BSA > 0.25% (excluding vermilions) at screening and baseline visits.

Cohort 1: In the dose-ranging period of the study, patients were randomized to receive daily ritlecitinib for 24 weeks, with or without a 4-week loading dose: 200 mg (loading dose)/50 mg, 100/50 mg, 50 mg, 30 mg, 10 mg, or placebo.

Cohort 2: Skin biopsies were taken at baseline and at Week 24 and analyzed by quantitative real-time PCR (qPCR), TaqMan Low Density Array (TLDA), RNA-seq, and immunohistochemistry (IHC) for melanocyte, Th1/Th2 markers, and co-stimulatory molecules as previously described [32]. Patients with a greater number of active lesions than stable lesions were considered “patients with more active than stable lesions”, while patients with a greater number of stable lesions were considered “patients with more stable than active lesions”. Patients with similar numbers of both active and stable lesions were excluded from these analyses.

Outcomes

Central photograph reviewers categorized all lesions as either active or stable, then evaluated depigmentation extent (100%, 90%, 75%, 50%, 25%, or 10%) at baseline and at Week 24 using photographs of both active lesions and stable lesions other than on the face as target lesions. Then each mean percent change from baseline (%CFB) was measured.

qPCR

TLDA cards (Thermo Fisher) were used for qPCR. Eukaryotic 18 S recombinant RNA was used as an endogenous control. Expression values were normalized to Rplp0.

IHC

IHC was performed on frozen skin sections as previously described [33, 34], using purified mouse anti-human antibodies (Table S1).

Serum protein quantification

Blood was collected, centrifuged, and stored at − 80oC. Aliquots were analyzed by the ultrasensitive proteomic OLINK Proseek multiplex assay (a proximity extension assay using oligonucleotide-labeled antibody probe pairs), using target cardiovascular disease II, cardiovascular disease III, immuno-oncology, and neurology multiplex panels, as previously described [35, 36].

Lesion sample status evaluation

Central photograph reviewers determined the overall activity status of all lesions at baseline and at all timepoints. Active lesions were defined as progressive and one of the following: confetti-like lesions, trichrome lesions, and Koebner phenomenon types 2a/b [37], while stable lesions were identified as lesions that did not show active signs (absence of confetti-like pattern, trichrome appearance, and Koebner phenomenon type 2a/2b).

Statistical analysis

The least squares mean with 90% CI was calculated for depigmentation using an analysis of covariance model at Week 24, which included treatment, baseline central read rate, and Fitzpatrick skin type as covariates. For all analyses here, the 200/50-mg, 100/50-mg, and 50-mg groups were pooled. One-sided unadjusted P-values were reported.

RNA-seq data were log-2 transformed with voom transform [38] and modeled using a mixed-effect model with time, treatment, and tissue interaction as a fixed effect and a random effect for each participant (using the R LIMMA package). The Benjamini-Hochberg procedure was used to adjust P-values for multiple hypotheses by controlling the FDR. FDR < 0.1 was determined as a criterion for overall statistically significant findings. Normalized PCR values and serum protein measures (normalized protein expression) were also modeled using a mixed-effect model with time, treatment, and tissue interaction as a fixed effect and a random effect for each participant (using the R nlme [nonlinear mixed-effects] package). Gene set variation analysis (GSVA; z-score) was also used to evaluate different immune pathways. For baseline serum protein analyses, a linear model was utilized to evaluate differential proteins between stable and active lesions. A linear mixed model was used to evaluate changes in protein levels from baseline by treatment group, timepoint, and lesion type.

Results

Baseline characteristics

Cohort 1: in total, 364 patients were randomized to daily ritlecitinib 50 mg (with or without a 4-week 100-mg or 200-mg daily loading dose; N = 199), 30 mg (N = 50), 10 mg (N = 49), or placebo (N = 66) (Table S2; [31]). A total of 298 patients completed the dose-ranging period.

Cohort 2: 65 patients participated in a skin biopsy sub-study [32]. Patients in the sub-study were on average 44.9 years old, 52% were female, and 68% were White (Table S3). Mean (SD) disease duration was 19.8 (12.5) years. Out of 65 patients, 31 patients had more active than stable lesions, and 27 patients had more stable than active lesions. Seven patients had similar numbers of active and stable lesions and were excluded from the analyses.

Baseline biomarkers comparisons

To examine the differences between active lesions and stable lesions at baseline, each sample was categorized as active or stable lesion based on photograph review, followed by RNA-seq, qPCR, and IHC. 136, 33, 32, and 56 pairs of target lesions were evaluated from the 50-mg, 30-mg, 10-mg, and placebo groups, respectively. 183, 28, 44, and 62 pairs of target lesions (at baseline and at Week 24) were evaluated from the 50-mg, 30-mg, 10-mg, and placebo groups, respectively.

When examining biopsied skin samples from Cohort 2 by RNA-seq at baseline, no statistically significant genes were found when comparing: (1) between lesions from patients with more active than stable lesions and lesions from patients with more stable than active lesions (Fig. S1a), (2) between non-lesional skin from patients with more active than stable lesions and non-lesional skin from patients with more stable than active lesions (Fig. S1a), or (3) between “lesions vs. non-lesions in patients with more active than stable lesions” vs. “lesions vs. non-lesions in patients with more stable than active lesions” (“delta-delta” comparisons; Fig. S1b). Statistically significant genes were observed in “delta” comparisons of differences in “lesions vs. non-lesions” in patients with more active than stable lesions, patients with more stable than active lesions, or all patients in Cohort 2. Overall, non-lesional skin displayed significantly higher expression of melanocyte function- and development-associated genes such as PMEL, DCT, and SLC24A5, while lesions showed upregulation of apoptosis-associated genes such as XAF1 (Fig. 1a left, Table S4, false discovery rate [FDR] < 0.05). When comparing lesions and non-lesional skin in patients with more active than stable lesions, a different set of genes was significantly upregulated or downregulated (Fig. 1a middle, Table S4, FDR < 0.05). When comparing lesions and non-lesional skin in patients with more stable than active lesions, a third set of genes was significantly upregulated or downregulated. Melanocyte-associated genes such as L1CAM, FOXD3, and GREB1 showed significantly increased expression in non-lesional skin (Fig. 1a right, Table S4, FDR < 0.05). Compared with non-lesional skin, lesional skin showed significantly increased expression of genes such as LARP7, and HMMR.

Fig. 1 Top 10 genesa upregulated or downregulated in vitiligo lesions as compared with non-lesional skin at baseline from all patients in Cohort 2, patients with more active than stable lesions, and patients with more stable than active lesions. a Defined as FDR < 0.05. b Gene associated with melanocyte development/regulation or vitiligo (based on PubMed search)

qPCR and TLDA showed that active lesions expressed higher gene levels of IFNG and CCL5 than stable lesions (Fig. S2, P < 0.05), although this trend was not reflected by RNA-seq.

At the protein level at baseline measured by IHC, stable and active lesions showed similar expression levels of melanocyte markers (Fig. 2a), but active lesions tended to contain greater numbers of CD3/CD8+ T-cell infiltrates than stable lesions (Fig. 2b, P < 0.1). The only difference noted was when measured by IHC, epidermal CD103 expression levels were higher in active lesions vs. stable lesions (Fig. S2, P < 0.05).

In patients with more active than stable lesions, significantly higher serum blood protein levels of CXCL9 (P = 0.004) and PD-L1 (P = 0.0007) were observed at baseline compared with patients with more stable than active lesions (Fig. 2c) as measured by proteomics, while HO-1 serum protein levels were significantly higher in patients with more stable than active lesions (P = 0.002).

Fig. 2 (a) Melanocyte marker and (b) CD3 and CD8 protein levels by IHC at baseline in active lesions and stable lesions in patients in Cohort 2. (c) Differential protein levels in blood serum of patients with more active than stable lesions and patients with more stable than active lesions (Cohort 2) as measured by proteomics at baseline. **P < 0.01, ***P < 0.001, patients with more active than stable lesions vs. patients with more stable than active lesions

Efficacy comparison between active lesions and stable lesions following ritlecitinib

We next investigated whether there were differences in repigmentation between active and stable lesions following 24 weeks of ritlecitinib treatment (excluding lesions on the face). For all patients enrolled in the phase 2b trial, within active lesions, ritlecitinib resulted in statistically significant reductions in the progression of depigmentation (mean [90% CI]) %CFB) in the 50-mg group (+ 0.59 [–1.50, 2.68]; P = 0.0096; N = 136) and in the 30-mg group (–1.45 [–5.47, 2.57]; P = 0.0090; N = 33) at Week 24 vs. placebo (+ 5.68 [2.59, 8.76]; N = 56) (Fig. 3a, Table S5, Fig. S3). A progressive increase in depigmentation in the placebo group was observed in active lesions.

Within stable lesions, ritlecitinib treatment resulted in a statistically significant reduction in depigmentation (an increase in repigmentation) in the 50-mg group (–6.35 [–8.45, − 4.26]; P = 0.0016; N = 183) and in the 30-mg group (–7.98 [–12.95, − 3.01]; P = 0.0090; N = 28) at Week 24 compared with placebo (+ 0.51 [–2.89, 3.91]; N = 62) (Fig. 3b, Table S5, Fig. S3). Depigmentation did not change in the placebo group in stable lesions.

Fig. 3 Mean %CFB of clinical depigmentation in (a) active lesions and (b) stable lesions at Week 24 in Cohort 1. %CFB, percent change from baseline; CI, confidence interval

Changes in biomarkers between active lesions and stable lesions following ritlecitinib

To examine the molecular effects of ritlecitinib on active and stable lesions in patients with active NSV, biopsied samples were analyzed by RNA-seq, qPCR, and IHC, and blood samples were analyzed by proteomics.

GSVA analysis revealed that both active and stable lesions displayed significantly (P < 0.01 and P < 0.1, respectively) decreased expression of Th1 markers (Fig. S4, markers were previously reported in patients with alopecia areata who were treated with ritlecitinib 50 mg [39]). At Week 24 compared with baseline, both active and stable lesions of patients in the 50-mg groups displayed a trend towards decreased expression of Th2 markers (Fig. S5, markers were previously reported in patients with alopecia areata [39]). RNA-seq analysis did not show statistically significant genes unique to active lesions or stable lesions in response to ritlecitinib treatment.

qPCR and TLDA were also performed for a large panel of immune and melanocyte markers to confirm RNA-seq results. When measured by qPCR, both active and stable lesions displayed significantly decreased expression of Th1 markers (IFNG, CXCL9, CXCR3; Fig. 4a, P < 0.05) and Th2 markers (CCR4, CCL18, and CCL13; Fig. 4b, P < 0.05) at Week 24 compared with baseline in patients in the 50-mg groups. However, qPCR and TLDA did not show statistically significant genes unique to active or stable lesions in response to ritlecitinib, although there was a trend towards increased levels of melanocyte markers (tyrosinase, TYRP1) in stable lesions vs. active lesions (data not shown, no statistical significance).

Fig. 4 (a) Th1 markers and (b) Th2 markers by qPCR at Week 24 patients with more active than stable lesions and patients with more stable than active lesions (Cohort 2). lgFCH, log fold change; Th1, T helper Type 1; Th2, T helper Type 2. Red symbols: *P < 0.05 vs. baseline; ** P < 0.01; *** P < 0.001. Black symbols: +P < 0.1 vs. placebo; * P < 0.05 vs. placebo; ** P < 0.01

We previously reported decreased expression levels of co-stimulatory molecules in response to ritlecitinib [32]. Here, we next investigated co-stimulatory molecules in lesions of patients with active NSV using RNA-seq and qPCR to examine any differences between active lesions and stable lesions. Both active lesions and stable lesions in the 50-mg groups displayed significantly decreased expression of co-stimulatory molecules and T-cell activation molecules such as CD86, CD28, inducible T-cell co-stimulator (ICOS), CTLA4, and PD-1 at Week 24 compared with baseline (Fig. 5, P < 0.05). A significant decrease in co-stimulatory molecules CD86, CD28, and ICOS in stable lesions was observed in the 30-mg group at Week 24 vs. baseline and vs. placebo (P < 0.05). This trend was not observed in active lesions.

Fig. 5 Co-stimulatory molecules by RNA-seq and qPCR at Week 24 in patients with more active than stable and patients with more stable than active lesions (Cohort 2). lgFCH, log fold change. Red symbols: +P < 0.1 vs. baseline; *P < 0.05 vs. baseline; **P < 0.01 vs. baseline; ***P < 0.001 vs. baseline. Black symbols: +P < 0.1 vs. placebo; *P < 0.05 vs. placebo; **P < 0.01 vs. placebo

At Week 24, stable lesions of patients in the ritlecitinib 50-mg group displayed a trend towards increased number of melanocytes in the epidermis compared with placebo when measured by IHC using melanocyte markers TYRP1 and Melan-A (P < 0.1, Fig. S6a). Active lesions also displayed a trend towards increase in number of melanocytes but to a small extent, as compared with stable lesions (no statistical significance between active and stable lesions at Week 24). Additionally, at Week 24 patients in the ritlecitinib 50-mg dose groups showed a significant reduction in T-cell infiltrates in both stable and active lesions (Fig. S6b, P < 0.05). Patients receiving placebo displayed no trend toward reduction in T-cell infiltrates.

Finally, we investigated serum inflammatory/immune markers using proteomics to examine any differences between patients with more active than stable lesions and patients with more stable than active lesions in response to ritlecitinib. Compared with baseline, serum from patients with more active than stable lesions receiving 50-mg ritlecitinib showed a significant decrease from baseline in the ICOS marker ICOSLG at Week 24 (Fig. 6, P ≤ 0.05). All patients who received 50-mg or 30-mg ritlecitinib showed significant decreases from baseline in markers of NK cell activation (Fig. 6, P < 0.05). In patients with more active than stable lesions who received 10 mg or placebo, significant increases from baseline in levels of inflammatory marker SLAMF7 at Week 24 were observed (Fig. 6, P < 0.05).

Fig. 6 Change from baseline in serum levels of ICOSLG, NK cell activation markers, and inflammatory marker by proteomics at Week 24 in patients with more active than stable and patients with more stable than active lesions (Cohort 2). NPX, normalized protein expression. *P < 0.05 vs. baseline; **P < 0.01 vs. baseline

Discussion

Clinically active vitiligo lesions can be differentiated from stable lesions macroscopically based on the presence of confetti-like lesions, trichrome lesions, or Koebner phenomenon types 2a/b [37]. We hypothesized that many key inflammatory biomarkers contributing to the formation of active vitiligo lesions could be identified at the gene and protein levels, as compared with stable lesions, by investigating skin and serum samples from patients with active NSV. However, the differences between active lesions and stable lesions at baseline were minimal. Statistically significant differences were only observed in the protein levels of CD103 (through IHC) and the expression levels of IFNG and CCL5 (through qPCR). Differences were only observed through RNA-seq analysis when the genes were compared between lesions vs. non-lesion (delta-comparison) but not by comparison of either lesions, non-lesions, or “lesions vs. non-lesions in patients with a more active than stable lesions” vs. “lesions vs. non-lesions in patients with a more stable than active lesions” (delta-delta comparison). Since most of the genes identified here have not previously been identified as a marker associated with melanogenesis or vitiligo pathogenesis, future studies are required to confirm these findings.

Gene expression-level analyses showed higher expression levels of IFN-γ and CCL5 in active lesions than stable lesions. As IFN-γ plays a crucial role in vitiligo pathogenesis [40], it is not surprising that inflamed active lesions express higher levels of IFN-γ. There was also increased CCL5 expression in the active lesions [41]. IHC analysis showed higher protein levels of CD103 (integrin αE) in the epidermis of active lesions compared with stable lesions. Future studies may elucidate the role of CD103 in active vitiligo lesions.

At baseline, serum from patients with more active than stable lesions showed significantly higher levels of CXCL9 and PD-L1 and a lower level of HO-1 than serum from patients with more stable than active lesions. Previously, increased CXCL9 serum levels were reported in patients with active lesions [14], as CXCL9 together with CXCL10 plays key roles in the activation and recruitment of CD8+/CXCR3+ T cells [42]; however, this is the first report showing increased PD-L1 and decreased HO-1 serum levels in patients with more active than stable lesions. Although the PD-1/PD-L1 pathway is well studied in melanoma, and it has been shown that anti-PD-1 and anti-PD-L1 therapy may result in depigmentation in patients with melanoma, this pathway has not been fully elucidated in vitiligo [43]. Since ritlecitinib resulted in decreased PD-1 expression in both active and stable lesions, downregulating the PD-1/PD-L1 pathway may have a therapeutic effect on patients with vitiligo. By contrast, HO-1 is an antioxidant that participates in the oxidative stress response [44] and is a functional modulator of Tregs in vitiligo [45]. The level of HO-1 in Tregs is decreased in patients with vitiligo and treatment of Tregs with Hemin, an agonist of HO-1, restored Treg function in vitro [45]. Enhancing serum HO-1 levels via an agonist may show clinical efficacy in patients with active vitiligo, although further investigations are required.

This was the first study focusing on the differential effects between active and stable lesions in patients with active vitiligo treated with a JAK3/TEC family kinase inhibitor on both clinical measures (depigmentation) and molecular signatures. In active lesions, placebo-treated patients showed progressive depigmentation at Week 24, whereas the progression of depigmentation was halted in those receiving 50-mg or 30-mg ritlecitinib, suggesting that ritlecitinib stabilizes vitiligo progression in active lesions. Repigmentation of active lesions may occur at a later stage than 24 weeks, suggesting that longer studies are needed to fully understand the effects of ritlecitinib on repigmentation of active lesions. By contrast, repigmentation of stable lesions was observed in patients receiving ritlecitinib for 24 weeks, whereas no improvement was observed with placebo. The degree of improvement with ritlecitinib compared with placebo was similar between active lesions and stable lesions. Thus, oral ritlecitinib treatment is beneficial in patients with both active and stable lesions, although longer treatment is required to fully observe the efficacy in active lesions.

Changes in melanocyte biomarkers from skin biopsies of active and stable lesions were consistent with the clinical findings. These results indicate that both types of lesions display CD3+ T-cell and CD8+ T-cell infiltrates, although active lesions trended towards greater numbers of infiltrates. Additionally, gene expression–based analyses showed that the response to ritlecitinib was similar between stable and active lesions in terms of decreased expression levels of Th1 markers, Th2 markers, and co-stimulatory molecules. As we did not observe many significant differences between active and stable lesions at baseline, the key factors contributing to the difference between active/progressive lesions and stable lesions may be limited, and overall inflammation may be similar between stable and active vitiligo lesions.

Serum from patients with more active than stable lesions showed reduced levels of ICOSLG, a co-stimulatory molecule, and SLAMF7, an inflammatory marker expressed on CD8+ T cells, B cells, and NK cells [46] in response to ritlecitinib; these reductions were not observed in patients with more stable than active lesions. These differences in activation and inflammatory molecules may contribute to the faster response of stable lesions than active lesions, although further investigations are necessary.

This study had some limitations. The treatment period was only 24 weeks, and the efficacy and molecular effects of longer-term therapy remain to be evaluated, particularly on active lesions that may require longer treatment to increase melanocyte markers and achieve repigmentation. Additionally, the number of patients for the biomarker portion of this study was limited. Lastly, patients were required to have ≥ 1 active lesion; therefore, patients who had only stable lesions were not evaluated.

Collectively, these data provide for the first time clinical and molecular evidence that systemic ritlecitinib stabilizes active lesions while promoting repigmentation of stable lesions in patients with vitiligo.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Acknowledgements

This study was funded by Pfizer. The authors thank patients and families, investigators, research coordinators, and site staff. The authors would like to extend a special thank you to Dr. Ana B Pavel, Dr. Anindita Banerjee, and Dr. Iltefat Hamzavi for their contributions in presenting this data at the 2022 American Academy of Dermatology’s Annual Meeting, and Dr. Amit Pandya for his support in developing the methodology. Medical writing support was provided by Carolyn Maskin, PhD, and Ellen Mercado, PhD, of Nucleus Global and was funded by Pfizer.

Author contributions

Y. Yamaguchi, E. Peeva, and E. Guttman-Yassky conceptualized the study and created the methodology. A. Sloan contributed the software. E. Del Duca validated the study. A. Sloan and J. Bar conducted the formal analysis. R. Shore and K. Ezzedine led the investigation. D. Thaci, A. Ganesan, and G. Han provisioned resources. A. Sloan, Z. Ye, P. Facheris and E. Del Duca worked on data curation. All authors contributed to writing (both the original draft and reviewing and editing). Y. Yamaguchi and E. Del Duca contributed to the visualization. E. Peeva and E. Guttman-Yassky supervised. Project administration was conducted by Y. Yamaguchi.

Data availability

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information. Biomarker-specific data are available from the corresponding author upon reasonable request.

Declarations

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent to publish

Patients signed informed consent regarding publishing their data and photographs.

Conflict of interest

Y. Yamaguchi, E. Peeva, L.A. Cox, A. Banerjee, and A. Sloan are employees of Pfizer, or were employees of Pfizer when this analysis was conducted and may hold stock and/or stock options with Pfizer. R. Shore declares serving as an investigator and consultant for Pfizer, and as a consultant and advisor for 2020 GeneSystems. D. Thaci declares serving as a consultant, investigator, speaker, and participating in scientific advisory boards for AbbVie, Almirall, Amgen, Biogen Idec, Bristol Myers Squibb, Janssen-Cilag, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Samsung, Sanofi, and UCB; and has received research/educational grants from AbbVie, LEO Pharma, and Novartis. A.K. Ganesan declares serving as a consultant for AbbVie, Allergan Aesthetics, and Viela Bio. K. Ezzedine declares serving as a consultant for Incyte, La Roche Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. E. Guttman-Yassky declares being an employee of Mount Sinai receiving research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Celgene, Dermavant, DS Biopharma, Eli Lilly, Galderma, Glenmark/Ichnos Sciences, Innovaderm Research, Janssen, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron Pharmaceuticals, Inc., Sienna Biopharma, UCB, and Union Therapeutics/AntibioTx; and is a consultant for AbbVie, Aditum Bio, Almirall, Alpine, Amgen, Arena, Asana Biosciences, AstraZeneca, Bluefin Biomedicine, Boehringer Ingelheim, Boston Pharmaceuticals, Botanix, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Clinical Outcome Solutions, DBV, Dermavant Sciences, Dermira Inc, Douglas Pharmaceutical, DS Biopharma, Eli Lilly, EMD Serono, Evelo Bioscience, Evidera, FIDE, Galderma, GlaxoSmithKline, Haus Bioceuticals, Ichnos Sciences, Incyte, Kyowa Kirin, Larrk Bio, LEO Pharma, Medicxi, Medscape, Neuralstem, Noble Insights, Novan, Novartis, Okava Pharmaceuticals, Pandion Therapeutics, Pfizer, Principia Biopharma, RAPT Therapeutics, Realm, Regeneron Pharmaceuticals Inc, Sanofi, SATO Pharmaceutical, Sienna Biopharma, Seanergy Dermatology, Seelos Therapeutics, Serpin Pharma, Siolta Therapeutics, Sonoma Biotherapeutics, Sun Pharma, Target PharmaSolutions and Union Therapeutics, Vanda Pharmaceuticals, Ventyx Biosciences, and Vimalan. G. Han declares being an investigator for Amgen, Athenex, Boehringer Ingelheim, Bond Avillion, Bristol Myers Squibb, Celgene, Eli Lilly, Novartis, Janssen, MC2, PellePharm, Pfizer, and UCB; and a consultant, advisor, or speaker for Abbvie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Dermavant, Dermtech, Eli Lilly, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, SUN Pharmaceuticals, and UCB. E. Del Duca and J. Bar declare no interests. P. Facheris has served as a consultant for Eli Lilly. The study is sponsored by Pfizer. Medical writing support was provided by Ellen Mercado, PhD, and Carolyn Maskin, PhD, of Nucleus Global and funded by Pfizer.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Bergqvist C Ezzedine K Vitiligo: a review Dermatology 2020 236 571 592 10.1159/000506103 32155629
Bergqvist C, Ezzedine K (2020) Vitiligo: a review. Dermatology 236:571–592. 10.1159/00050610332155629 10.1159/000506103
2. Elbuluk N Ezzedine K Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients Dermatol Clin 2017 35 117 128 10.1016/j.det.2016.11.002 28317521
Elbuluk N, Ezzedine K (2017) Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin 35:117–128. 10.1016/j.det.2016.11.00228317521 10.1016/j.det.2016.11.002
3. Rodrigues M Ezzedine K Hamzavi I Pandya AG Harris JE Group VW New discoveries in the pathogenesis and classification of vitiligo J Am Acad Dermatol 2017 77 1 13 10.1016/j.jaad.2016.10.048 28619550
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Group VW (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77:1–13. 10.1016/j.jaad.2016.10.04828619550 10.1016/j.jaad.2016.10.048
4. Roohaninasab M Mansouri P Seirafianpour F Naeini AJ Goodarzi A Therapeutic options and hot topics in vitiligo with special focus on pediatrics’ vitiligo: a comprehensive review study Dermatol Ther 2021 34 e14550 10.1111/dth.14550 33200859
Roohaninasab M, Mansouri P, Seirafianpour F, Naeini AJ, Goodarzi A (2021) Therapeutic options and hot topics in vitiligo with special focus on pediatrics’ vitiligo: a comprehensive review study. Dermatol Ther 34:e14550. 10.1111/dth.1455033200859 10.1111/dth.14550
5. Martins C Migayron L Drullion C Jacquemin C Lucchese F Rambert J Vitiligo skin t cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through JAK signaling J Invest Dermatol 2021 10.1016/j.jid.2021.09.015 34655610
Martins C, Migayron L, Drullion C, Jacquemin C, Lucchese F, Rambert J et al (2021) Vitiligo skin t cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through jak signaling. J Invest Dermatol. 10.1016/j.jid.2021.09.01534655610 10.1016/j.jid.2021.09.015
6. Faraj S Kemp EH Gawkrodger DJ Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors Clin Exp Immunol 2021 10.1093/cei/uxab002
Faraj S, Kemp EH, Gawkrodger DJ (2021) Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. Clin Exp Immunol. 10.1093/cei/uxab00210.1093/cei/uxab002
7. Schwartz DM Bonelli M Gadina M O’Shea JJ Type i/ii cytokines, jaks, and new strategies for treating autoimmune diseases Nat Rev Rheumatol 2016 12 25 36 10.1038/nrrheum.2015.167 26633291
Schwartz DM, Bonelli M, Gadina M, O’Shea JJ (2016) Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12:25–36. 10.1038/nrrheum.2015.16726633291 10.1038/nrrheum.2015.167
8. Boukhedouni N, Martins C, Darrigade AS, Drullion C, Rambert J, Barrault C et al (2020) Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight 5. 10.1172/jci.insight.133772
9. Richmond JM Bangari DS Essien KI Currimbhoy SD Groom JR Pandya AG Keratinocyte-derived chemokines orchestrate t-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease J Invest Dermatol 2017 137 350 358 10.1016/j.jid.2016.09.016 27686391
Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG et al (2017) Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol 137:350–358. 10.1016/j.jid.2016.09.01627686391 10.1016/j.jid.2016.09.016
10. Czarnowicki T He H Leonard A Kim HJ Kameyama N Pavel AB Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases J Allergy Clin Immunol 2019 143 2095 2107 10.1016/j.jaci.2018.11.031 30576756
Czarnowicki T, He H, Leonard A, Kim HJ, Kameyama N, Pavel AB et al (2019) Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. J Allergy Clin Immunol 143:2095–2107. 10.1016/j.jaci.2018.11.03130576756 10.1016/j.jaci.2018.11.031
11. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC et al (2012) Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 25(E1–13). 10.1111/j.1755-148X.2012.00997.x
12. Sahni K Parsad D Stability in Vitiligo: is there a perfect way to predict it? J Cutan Aesthet Surg 2013 6 75 82 10.4103/0974-2077.112667 24023428
Sahni K, Parsad D (2013) Stability in vitiligo: is there a perfect way to predict it? J Cutan Aesthet Surg 6:75–82. 10.4103/0974-2077.11266724023428 10.4103/0974-2077.112667
13. Dwivedi M Laddha NC Arora P Marfatia YS Begum R Decreased regulatory t-cells and cd4(+) /cd8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo Pigment Cell Melanoma Res 2013 26 586 591 10.1111/pcmr.12105 23574980
Dwivedi M, Laddha NC, Arora P, Marfatia YS, Begum R (2013) Decreased regulatory T-cells and CD4(+) /CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 26:586–591. 10.1111/pcmr.1210523574980 10.1111/pcmr.12105
14. Wang XX Wang QQ Wu JQ Jiang M Chen L Zhang CF Xiang LH Increased expression of cxcr3 and its ligands in patients with vitiligo and cxcl10 as a potential clinical marker for vitiligo Br J Dermatol 2016 174 1318 1326 10.1111/bjd.14416 26801009
Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, Xiang LH (2016) Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol 174:1318–1326. 10.1111/bjd.1441626801009 10.1111/bjd.14416
15. Zhang L Kang Y Chen S Wang L Jiang M Xiang L Circulating CCL20: a potential biomarker for active vitiligo together with the number of th1/17 cells J Dermatol Sci 2019 93 92 100 10.1016/j.jdermsci.2018.12.005 30655106
Zhang L, Kang Y, Chen S, Wang L, Jiang M, Xiang L (2019) Circulating CCL20: a potential biomarker for active vitiligo together with the number of Th1/17 cells. J Dermatol Sci 93:92–100. 10.1016/j.jdermsci.2018.12.00530655106 10.1016/j.jdermsci.2018.12.005
16. Benzekri L Gauthier Y Clinical markers of vitiligo activity J Am Acad Dermatol 2017 76 856 862 10.1016/j.jaad.2016.12.040 28245942
Benzekri L, Gauthier Y (2017) Clinical markers of vitiligo activity. J Am Acad Dermatol 76:856–862. 10.1016/j.jaad.2016.12.04028245942 10.1016/j.jaad.2016.12.040
17. Abdallah M El-Mofty M Anbar T Rasheed H Esmat S Al-Tawdy A Cxcl-10 and interleukin-6 are reliable serum markers for vitiligo activity: a multicenter cross-sectional study Pigment Cell Melanoma Res 2018 31 330 336 10.1111/pcmr.12667 29094481
Abdallah M, El-Mofty M, Anbar T, Rasheed H, Esmat S, Al-Tawdy A et al (2018) CXCL-10 and interleukin-6 are reliable serum markers for vitiligo activity: a multicenter cross-sectional study. Pigment Cell Melanoma Res 31:330–336. 10.1111/pcmr.1266729094481 10.1111/pcmr.12667
18. Lin F Hu W Xu W Zhou M Xu AE Cxcl9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation Sci Rep 2021 11 18298 10.1038/s41598-021-97296-2 34521889
Lin F, Hu W, Xu W, Zhou M, Xu AE (2021) CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation. Sci Rep 11:18298. 10.1038/s41598-021-97296-234521889 10.1038/s41598-021-97296-2
19. Rodrigues M Ezzedine K Hamzavi I Pandya AG Harris JE Group VW Current and emerging treatments for vitiligo J Am Acad Dermatol 2017 77 17 29 10.1016/j.jaad.2016.11.010 28619557
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Group VW (2017) Current and emerging treatments for vitiligo. J Am Acad Dermatol 77:17–29. 10.1016/j.jaad.2016.11.01028619557 10.1016/j.jaad.2016.11.010
20. Lee JH Kwon HS Jung HM Lee H Kim GM Yim HW Bae JM Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis JAMA Dermatol 2019 155 929 938 10.1001/jamadermatol.2019.0696 31141108
Lee JH, Kwon HS, Jung HM, Lee H, Kim GM, Yim HW, Bae JM (2019) Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol 155:929–938. 10.1001/jamadermatol.2019.069631141108 10.1001/jamadermatol.2019.0696
21. Bae JM Jung HM Hong BY Lee JH Choi WJ Kim GM Phototherapy for vitiligo: a systematic review and meta-analysis JAMA Dermatol 2017 153 666 674 10.1001/jamadermatol.2017.0002 28355423
Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Kim GM (2017) Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol 153:666–674. 10.1001/jamadermatol.2017.000228355423 10.1001/jamadermatol.2017.0002
22. Wada-Irimada M Tsuchiyama K Sasaki R Hatchome N Watabe A Kimura Y Efficacy and safety of i.V. Methylprednisolone pulse therapy for vitiligo: a retrospective study of 58 therapy experiences for 33 vitiligo patients J Dermatol 2021 48 1090 1093 10.1111/1346-8138.15858 33768620
Wada-Irimada M, Tsuchiyama K, Sasaki R, Hatchome N, Watabe A, Kimura Y et al (2021) Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: a retrospective study of 58 therapy experiences for 33 vitiligo patients. J Dermatol 48:1090–1093. 10.1111/1346-8138.1585833768620 10.1111/1346-8138.15858
23. Migayron L Boniface K Seneschal J Vitiligo, from physiopathology to emerging treatments: a review Dermatol Ther (Heidelb) 2020 10 1185 1198 10.1007/s13555-020-00447-y 32949337
Migayron L, Boniface K, Seneschal J (2020) Vitiligo, from physiopathology to emerging treatments: a review. Dermatol Ther (Heidelb) 10:1185–1198. 10.1007/s13555-020-00447-y32949337 10.1007/s13555-020-00447-y
24. Damsky W King BA Jak inhibitors in dermatology: the promise of a new drug class J Am Acad Dermatol 2017 76 736 744 10.1016/j.jaad.2016.12.005 28139263
Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76:736–744. 10.1016/j.jaad.2016.12.00528139263 10.1016/j.jaad.2016.12.005
25. Telliez JB Dowty ME Wang L Jussif J Lin T Li L Discovery of a jak3-selective inhibitor: functional differentiation of jak3-selective inhibition over pan-jak or jak1-selective inhibition ACS Chem Biol 2016 11 3442 3451 10.1021/acschembio.6b00677 27791347
Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L et al (2016) Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol 11:3442–3451. 10.1021/acschembio.6b0067727791347 10.1021/acschembio.6b00677
26. Xu H Jesson MI Seneviratne UI Lin TH Sharif MN Xue L Pf-06651600, a dual jak3/tec family kinase inhibitor ACS Chem Biol 2019 14 1235 1242 10.1021/acschembio.9b00188 31082193
Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L et al (2019) PF-06651600, a dual JAK3/TEC family kinase inhibitor. ACS Chem Biol 14:1235–1242. 10.1021/acschembio.9b0018831082193 10.1021/acschembio.9b00188
27. Qi F Liu F Gao L Janus kinase inhibitors in the treatment of vitiligo: a review Front Immunol 2021 12 790125 10.3389/fimmu.2021.790125 34868078
Qi F, Liu F, Gao L (2021) Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol 12:790125. 10.3389/fimmu.2021.79012534868078 10.3389/fimmu.2021.790125
28. Rosmarin D Passeron T Pandya AG Grimes P Harris JE Desai SR Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo N Engl J Med 2022 387 1445 1455 10.1056/NEJMoa2118828 36260792
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR et al (2022) Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med 387:1445–1455. 10.1056/NEJMoa211882836260792 10.1056/NEJMoa2118828
29. Sheikh A Rafique W Owais R Malik F Ali E Fda approves ruxolitinib (opzelura) for vitiligo therapy: a breakthrough in the field of dermatology Ann Med Surg (Lond) 2022 81 104499 10.1016/j.amsu.2022.104499 36147080
Sheikh A, Rafique W, Owais R, Malik F, Ali E (2022) FDA approves ruxolitinib (opzelura) for vitiligo therapy: a breakthrough in the field of dermatology. Ann Med Surg (Lond) 81:104499. 10.1016/j.amsu.2022.10449936147080 10.1016/j.amsu.2022.104499
30. King B Zhang X Harcha WG Szepietowski JC Shapiro J Lynde C Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial Lancet 2023 401 1518 1529 10.1016/S0140-6736(23)00222-2 37062298
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C et al (2023) Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 401:1518–1529. 10.1016/S0140-6736(23)00222-237062298 10.1016/S0140-6736(23)00222-2
31. Ezzedine K Peeva E Yamaguchi Y Cox LA Banerjee A Han G Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial J Am Acad Dermatol 2022 10.1016/j.jaad.2022.11.005 36370907
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G et al (2022) Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J Am Acad Dermatol. 10.1016/j.jaad.2022.11.00536370907 10.1016/j.jaad.2022.11.005
32. Guttman-Yassky E Duca ED Rosa JCD Bar J Ezzedine K Ye Z Improvements in immune/melanocyte biomarkers with jak3/tec family kinase inhibitor ritlecitinib in vitiligo J Allergy Clin Immunol 2024 153 161 172e8 10.1016/j.jaci.2023.09.021 37777018
Guttman-Yassky E, Duca ED, Rosa JCD, Bar J, Ezzedine K, Ye Z et al (2024) Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo. J Allergy Clin Immunol 153:161–172e8. 10.1016/j.jaci.2023.09.02137777018 10.1016/j.jaci.2023.09.021
33. Tintle S Shemer A Suárez-Fariñas M Fujita H Gilleaudeau P Sullivan-Whalen M Reversal of atopic dermatitis with narrow-band Uvb phototherapy and biomarkers for therapeutic response J Allergy Clin Immunol 2011 128 583 593 10.1016/j.jaci.2011.05.042 21762976
Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M et al (2011) Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 128:583–593. e1-421762976 10.1016/j.jaci.2011.05.042
34. Suárez-Fariñas M Tintle SJ Shemer A Chiricozzi A Nograles K Cardinale I Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities J Allergy Clin Immunol 2011 127 954 64e1 10.1016/j.jaci.2010.12.1124 21388663
Suárez-Fariñas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I et al (2011) Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 127:954–64e1. 10.1016/j.jaci.2010.12.112421388663 10.1016/j.jaci.2010.12.1124
35. Brunner PM Suárez-Fariñas M He H Malik K Wen HC Gonzalez J The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins Sci Rep 2017 7 8707 10.1038/s41598-017-09207-z 28821884
Brunner PM, Suárez-Fariñas M, He H, Malik K, Wen HC, Gonzalez J et al (2017) The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep 7:8707. https://doi.org/10.1038/s41598-017-09207-z 28821884 10.1038/s41598-017-09207-z
36. Carlsson AC Sundström J Carrero JJ Gustafsson S Stenemo M Larsson A Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria Eur J Prev Cardiol 2017 24 340 348 10.1177/2047487316676134 27794105
Carlsson AC, Sundström J, Carrero JJ, Gustafsson S, Stenemo M, Larsson A et al (2017) Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria. Eur J Prev Cardiol 24:340–348. 10.1177/204748731667613427794105 10.1177/2047487316676134
37. Goh BK Pandya AG Presentations, signs of activity, and differential diagnosis of vitiligo Dermatol Clin 2017 35 135 144 10.1016/j.det.2016.11.004 28317523
Goh BK, Pandya AG (2017) Presentations, signs of activity, and differential diagnosis of vitiligo. Dermatol Clin 35:135–144. 10.1016/j.det.2016.11.00428317523 10.1016/j.det.2016.11.004
38. Law CW Chen Y Shi W Smyth GK Voom: Precision weights unlock linear model analysis tools for rna-seq read counts Genome Biol 2014 15 R29 10.1186/gb-2014-15-2-r29 24485249
Law CW, Chen Y, Shi W, Smyth GK (2014) Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15:R29. 10.1186/gb-2014-15-2-r2924485249 10.1186/gb-2014-15-2-r29
39. Guttman-Yassky E Pavel AB Diaz A Zhang N Duca ED Estrada Y Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers J Allergy Clin Immunol 2022 149 1318 1328 10.1016/j.jaci.2021.10.036 34863853
Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Duca ED, Estrada Y et al (2022) Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol 149:1318–1328. 10.1016/j.jaci.2021.10.03634863853 10.1016/j.jaci.2021.10.036
40. Frisoli ML Essien K Harris JE Vitiligo: mechanisms of pathogenesis and treatment Annu Rev Immunol 2020 38 621 648 10.1146/annurev-immunol-100919-023531 32017656
Frisoli ML, Essien K, Harris JE (2020) Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol 38:621–648. 10.1146/annurev-immunol-100919-02353132017656 10.1146/annurev-immunol-100919-023531
41. Yang L Yang S Lei J Hu W Chen R Lin F Xu AE Role of chemokines and the corresponding receptors in vitiligo: a pilot study J Dermatol 2018 45 31 38 10.1111/1346-8138.14004 29115683
Yang L, Yang S, Lei J, Hu W, Chen R, Lin F, Xu AE (2018) Role of chemokines and the corresponding receptors in vitiligo: a pilot study. J Dermatol 45:31–38. 10.1111/1346-8138.1400429115683 10.1111/1346-8138.14004
42. Frisoli ML Harris JE Vitiligo: mechanistic insights lead to novel treatments J Allergy Clin Immunol 2017 140 654 662 10.1016/j.jaci.2017.07.011 28778794
Frisoli ML, Harris JE (2017) Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin Immunol 140:654–662. 10.1016/j.jaci.2017.07.01128778794 10.1016/j.jaci.2017.07.011
43. Willemsen M Melief CJM Bekkenk MW Luiten RM Targeting the pd-1/pd-l1 axis in human vitiligo Front Immunol 2020 11 579022 10.3389/fimmu.2020.579022 33240267
Willemsen M, Melief CJM, Bekkenk MW, Luiten RM (2020) Targeting the PD-1/PD-L1 axis in human vitiligo. Front Immunol 11:579022. 10.3389/fimmu.2020.57902233240267 10.3389/fimmu.2020.579022
44. Jian Z Li K Song P Zhu G Zhu L Cui T Impaired activation of the nrf2-are signaling pathway undermines h2o2-induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo J Invest Dermatol 2014 134 2221 2230 10.1038/jid.2014.152 24662764
Jian Z, Li K, Song P, Zhu G, Zhu L, Cui T et al (2014) Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo. J Invest Dermatol 134:2221–2230. 10.1038/jid.2014.15224662764 10.1038/jid.2014.152
45. Zhang Q Cui T Chang Y Zhang W Li S He Y Ho-1 regulates the function of treg: Association with the immune intolerance in vitiligo J Cell Mol Med 2018 22 4335 4343 10.1111/jcmm.13723 29974998
Zhang Q, Cui T, Chang Y, Zhang W, Li S, He Y et al (2018) HO-1 regulates the function of Treg: Association with the immune intolerance in vitiligo. J Cell Mol Med 22:4335–4343. 10.1111/jcmm.1372329974998 10.1111/jcmm.13723
46. Malaer JD Mathew PA Cs1 (slamf7, cd319) is an effective immunotherapeutic target for multiple myeloma Am J Cancer Res 2017 7 1637 1641 28861320
Malaer JD, Mathew PA (2017) Cs1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. Am J Cancer Res 7:1637–164128861320
